Submitted:
14 September 2024
Posted:
16 September 2024
You are already at the latest version
Abstract

Keywords:
1. Introduction
1.1. Hypothesis and Objectives of Our Research
2. Materials and Methods
2.1. Data Collection and Study Design
2.2. Inclusion and Exclusion Criteria
2.3. Definition of Waves
2.4. Vaccination Rollout
2.5. Estimated Scenarios of the Unvaccinated Population
2.6. Mathematical modeling of hospitalizations and mortality
2.7. Machine Learning Algorithms
2.8. Fitting the Models
2.9. Statistical analyses
3. Results
3.1. Global Overview of the Pandemic
3.2. Vaccination Rollout
3.3. Hospitalizations and Deaths in an Estimated Scenario
4. Discussion
4.1. Descriptive Analyses
4.2. Vaccination Rollout
4.3. Modeling and Estimating Data in a Non-Vaccination Scenario
4.4. Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
| ARIMA | Auto-Regressive Integrated Moving Average |
| COVID-2019 | CoronaVirus Disease 2019 |
| EN | ElasticNet |
| EU/EEA | European Union/European Economic Area |
| LSTM | Long-Short Term Memory |
| MBDS-H | Minimum Basic Data Set at Hospitalization |
| SARS-CoV-2 | Severe Acute Respiratory Syndrome Coronavirus 2 |
| MCMC | Markov Chain with Monte Carlo |
| RF | RandomForest |
Appendix A. Descriptive Analyses




Appendix B. Mathematical Modeling of Hospitalizations and Mortality
References
- Hosseinzadeh, P.; Zareipour, M.; Baljani, E.; Moradali, M. Social Consequences of the COVID-19 Pandemic. A Systematic Review. Invest Educ Enferm 2022, 40, e10. [Google Scholar] [CrossRef] [PubMed]
- Mofijur, M.; Fattah, I.; Alam, M.; Islam, A.; Ong, H.; Rahman, S.; others. Impact of COVID-19 on the social, economic, environmental and energy domains: Lessons learnt from a global pandemic. Sustainable Production and Consumption 2021, 26, 343–359. [Google Scholar] [CrossRef]
- Osofsky, J.; Osofsky, H.; Mamon, L. Psychological and social impact of COVID-19. Psychological Trauma: Theory, Research, Practice, and Policy 2020, 12, 468–469. [Google Scholar] [CrossRef] [PubMed]
- Saladino, V.; Algeri, D.; Auriemma, V. The Psychological and Social Impact of Covid-19: New Perspectives of Well-Being. Frontiers in Psychology 2020, 11. [Google Scholar] [CrossRef]
- Patel, B.; Murphy, R.; Karanth, S.; Shiffaraw, S.; Peters, R.; Hohmann, S.; others. Surge in Incidence and Coronavirus Disease 2019 Hospital Risk of Death, United States, September 2020 to March 2021. Open Forum Infect Dis 2022, 9. [Google Scholar] [CrossRef]
- Delahoy, M.; Ujamaa, D.; Whitaker, M.; O’Halloran, A.; Anglin, O.; Burns, E.; others. Hospitalizations Associated with COVID-19 Among Children and Adolescents—COVID-NET, 14 States, March 1, 2020–August 14, 2021. MMWR Morb Mortal Wkly Rep 2021, 70, 1255–1260. [Google Scholar] [CrossRef]
- Taylor, C. COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status—COVID-NET, 14 States, July 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022, 71. [Google Scholar] [CrossRef] [PubMed]
- Havers, F.; Pham, H.; Taylor, C.; Whitaker, M.; Patel, K.; Anglin, O.; others. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022. JAMA Internal Medicine 2022, 182, 1071–1081. [Google Scholar] [CrossRef]
- de Sanidad, M. Situación actual Coronavirus. [cited 2023 Jan 24].
- Stefanelli, P.; Trentini, F.; Petrone, D.; Mammone, A.; Ambrosio, L.; Manica, M.; others. Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022. Euro Surveill 2022, 27, 2200125. [Google Scholar] [CrossRef]
- Assessment of the further spread and potential impact of the SARS-CoV-2 Omicron variant of concern in the EU/EEA, 19th update, 2022. [cited 2023 Oct 15].
- Markov, P.; Ghafari, M.; Beer, M.; Lythgoe, K.; Simmonds, P.; Stilianakis, N.; others. The evolution of SARS-CoV-2. Nat Rev Microbiol 2023, 21, 361–379. [Google Scholar] [CrossRef]
- Soheili, M.; Khateri, S.; Moradpour, F.; Mohammadzedeh, P.; Zareie, M.; Mortazavi, S.; others. The efficacy and effectiveness of COVID-19 vaccines around the world: a mini-review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials 2023, 22, 42. [Google Scholar] [CrossRef] [PubMed]
- Harder, T.; Koch, J.; Vygen-Bonnet, S.; Külper-Schiek, W.; Pilic, A.; Reda, S.; others. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Eurosurveillance 2021, 26. [Google Scholar] [CrossRef] [PubMed]
- Graña, C.; Ghosn, L.; Evrenoglou, T.; Jarde, A.; Minozzi, S.; Bergman, H.; others. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev 2022, 12, CD015477. [Google Scholar] [CrossRef]
- Yang, Z.; Jiang, Y.; Li, F.; Liu, D.; Lin, T.; Zhao, Z.; others. Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. The Lancet Microbe 2023, 4, e236–e246. [Google Scholar] [CrossRef]
- Watson, O.; Barnsley, G.; Toor, J.; Hogan, A.; Winskill, P.; Ghani, A. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022, 22, 1293–1302. [Google Scholar] [CrossRef]
- Zeng, B.; Gao, L.; Zhou, Q.; Yu, K.; Sun, F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Medicine 2022, 20, 200. [Google Scholar] [CrossRef]
- de Sanidad Consumo y Bienestar Social, M. Portal Estadistico. Area de Inteligencia de Gestion. [cited 2019 Jul 6].
- Data on COVID-19 vaccination in the EU/EEA, 2023. [cited 2023 Oct 15].
- Informe no 128 Situación de COVID-19 en España a 10 de mayo de 2022, 2022. [cited 2022 Jun 9].
- Gobierno de España. Estrategia de vacunación COVID-19.
- Rodriguez-Maroto, G.; Atienza-Diez, I.; Ares, S.; Manrubia, S. Vaccination strategies in structured populations under partial immunity and reinfection. medRxiv, 2021; 2021.11.23.21266766. [Google Scholar] [CrossRef]
- Tibshirani, R. Regression Shrinkage and Selection via the Lasso. Journal of the Royal Statistical Society Series B (Methodological) 1996, 58, 267–288. [Google Scholar] [CrossRef]
- Garcia-Carretero, R.; Vigil-Medina, L.; Barquero-Perez, O.; Ramos-Lopez, J. Relevant Features in Nonalcoholic Steatohepatitis Determined Using Machine Learning for Feature Selection. Metabolic Syndrome and Related Disorders 2019, 17, 444–451. [Google Scholar] [CrossRef]
- Garcia-Carretero, R.; Barquero-Perez, O.; Mora-Jimenez, I.; Soguero-Ruiz, C.; Goya-Esteban, R.; Ramos-Lopez, J. Identification of clinically relevant features in hypertensive patients using penalized regression: a case study of cardiovascular events. Medical & Biological Engineering & Computing 2019, 57, 2011–2026. [Google Scholar] [CrossRef]
- Garcia-Carretero, R.; Vigil-Medina, L.; Barquero-Perez, O.; Mora-Jimenez, I.; Soguero-Ruiz, C.; Goya-Esteban, R.; others. Logistic LASSO and Elastic Net to Characterize Vitamin D Deficiency in a Hypertensive Obese Population. Metabolic Syndrome and Related Disorders 2020, 18, 79–85. [Google Scholar] [CrossRef]
- Breiman, L. Random Forests. Machine Learning 2001, 45, 5–32. [Google Scholar] [CrossRef]
- Cutler, D.; Edwards Jr, T.; Beard, K.; Cutler, A.; Hess, K.; Gibson, J.; others. Random forests for classification in ecology. Ecology 2007, 88, 2783–2792. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Carretero, R.; Vazquez-Gomez, O.; Lopez-Lomba, M.; Gil-Prieto, R.; Gil-de Miguel, A. Insulin Resistance and Metabolic Syndrome as Risk Factors for Hospitalization in Patients with COVID-19: Pilot Study on the Use of Machine Learning. Metab Syndr Relat Disord 2023, 21, 443–452. [Google Scholar] [CrossRef]
- Garcia-Carretero, R.; Vigil-Medina, L.; Mora-Jimenez, I.; Soguero-Ruiz, C.; Barquero-Perez, O.; Ramos-Lopez, J. Use of a K-nearest neighbors model to predict the development of type 2 diabetes within 2 years in an obese, hypertensive population. Medical & Biological Engineering & Computing, 2020; 1–12. [Google Scholar] [CrossRef]
- Team, R.C. R: A Language and Environment for Statistical Computing, 2020. R Foundation for Statistical Computing.
- Farsalinos, K.; Poulas, K.; Kouretas, D.; Vantarakis, A.; Leotsinidis, M.; Kouvelas, D.; others. Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. primary and community healthcare. Toxicology Reports 2021, 8, 1–9. [Google Scholar] [CrossRef]
- Connors, M.; Graham, B.; Lane, H.; Fauci, A. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Ann Intern Med 2021, 174, 687–690. [Google Scholar] [CrossRef]
- Kustin, T.; Harel, N.; Finkel, U.; Perchik, S.; Harari, S.; Tahor, M.; others. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med 2021, 27, 1379–1384. [Google Scholar] [CrossRef]
- Wang, Z.; Muecksch, F.; Schaefer-Babajew, D.; Finkin, S.; Viant, C.; Gaebler, C.; others. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021, 595, 426–431. [Google Scholar] [CrossRef]
- Garcia-Carretero, R.; Vazquez-Gomez, O.; Ordoñez-Garcia, M.; Garrido-Peño, N.; Gil-Prieto, R.; Gil-de Miguel, A. Differences in Trends in Admissions and Outcomes among Patients from a Secondary Hospital in Madrid during the COVID-19 Pandemic: A Hospital-Based Epidemiological Analysis (2020-2022). Viruses 2023, 15, 1616. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Carretero, R.; Vazquez-Gomez, O.; Gil-Prieto, R.; Gil-de Miguel, A. Hospitalization burden and epidemiology of the COVID-19 pandemic in Spain (2020-2021). BMC Infect Dis 2023, 23, 476. [Google Scholar] [CrossRef]
- Barandalla, I.; Alvarez, C.; Barreiro, P.; de Mendoza, C.; González-Crespo, R.; Soriano, V. Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. International Journal of Infectious Diseases 2021, 112, 81–88. [Google Scholar] [CrossRef]
- Sentís, A.; Kislaya, I.; Nicolay, N.; Meijerink, H.; Starrfelt, J.; Martínez-Baz, I.; others. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged > 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. Eurosurveillance 2022, 27, 2200551. [Google Scholar] [CrossRef] [PubMed]
- Chyon, F.; Suman, M.; Fahim, M.; Ahmmed, M. Time series analysis and predicting COVID-19 affected patients by ARIMA model using machine learning. J Virol Methods 2022, 301, 114433. [Google Scholar] [CrossRef] [PubMed]
- Maleki, M.; Mahmoudi, M.; Wraith, D.; Pho, K. Time series modelling to forecast the confirmed and recovered cases of COVID-19. Travel Med Infect Dis 2020, 37, 101742. [Google Scholar] [CrossRef] [PubMed]
- Kırbaş, İ.; Sözen, A.; Tuncer, A.; Kazancıoğlu, F. Comparative analysis and forecasting of COVID-19 cases in various European countries with ARIMA, NARNN and LSTM approaches. Chaos Solitons Fractals 2020, 138, 110015. [Google Scholar] [CrossRef] [PubMed]
- Nabi, K.; Tahmid, M.; Rafi, A.; Kader, M.; Haider, M. Forecasting COVID-19 cases: A comparative analysis between recurrent and convolutional neural networks. Results Phys 2021, 24, 104137. [Google Scholar] [CrossRef]
- Makridakis, S.; Spiliotis, E.; Assimakopoulos, V.; Semenoglou, A.; Mulder, G.; Nikolopoulos, K. Statistical, machine learning and deep learning forecasting methods: Comparisons and ways forward. Journal of the Operational Research Society 2023, 74, 840–859. [Google Scholar] [CrossRef]
- Whittaker, C.; Walker, P.G.; Alhaffar, M.; Hamlet, A.; Djaafara, B.A.; Ghani, A.; Ferguson, N.; Dahab, M.; Checchi, F.; Watson, O.J. Under-reporting of deaths limits our understanding of true burden of covid-19. bmj 2021, 375. [Google Scholar] [CrossRef]





| All waves | First | Second | Third | Fourth | Fifth | Sixth | P value | |
|---|---|---|---|---|---|---|---|---|
| Hospital admissions | 498,789 | 115,356 | 127,114 | 126,623 | 51,006 | 54,570 | 24,120 | 0.001 |
| Sex (men) | 56.1% | 56.2% | 55.5% | 56.2% | 57.5% | 55.3% | 56.2% | 0.001 |
| Age, median (IQR) | 66 (28) | 69 (25) | 68 (28) | 69 (25) | 59 (24) | 57 (38) | 65 (28) | 0.001 |
| Hospital stay, median (IQR) | 8 (9) | 11.9 (9) | 8 (9) | 12.1 (9) | 7 (7) | 10.4 (8) | 6 (7) | 0.001 |
| ICU | ||||||||
| Admissions | 54,354 | 10,218 | 13,302 | 14,441 | 7,194 | 6,941 | 2,258 | 0.001 |
| ICU (%) | 10.9 | 8.9 | 10.5 | 11.4 | 14.1 | 12.7 | 9.4 | 0.001 |
| ICU stay, median (IQR) | 10 (21) | 11 (22.3) | 10 (21.4) | 11 (21.5) | 11 (21.4) | 10 (18.7) | 6 (9.1) | 0.001 |
| Mortality | ||||||||
| Deaths | 71,437 | 21,037 | 18,229 | 20,400 | 3,793 | 5,487 | 2,491 | 0.001 |
| Mortality rate (%) | 14.3 | 18.2 | 14.3 | 16.1 | 7.4 | 10.1 | 10.3 | 0.001 |
| Comorbidities | ||||||||
| Type 2 diabetes | 21.7 | 20.6 | 23.2 | 24.3 | 18.3 | 18.3 | 21.4 | 0.001 |
| Hypertension | 33.8 | 35.2 | 34.7 | 37.2 | 31.1 | 25.0 | 31.6 | 0.001 |
| AMI | 7.1 | 7.3 | 7.4 | 7.9 | 5.3 | 5.7 | 7.5 | 0.001 |
| CHF | 7.2 | 6.5 | 7.8 | 8.4 | 4.2 | 6.8 | 7.9 | 0.001 |
| Dementia | 4.8 | 5.5 | 5.4 | 5.2 | 2.1 | 3.9 | 3.6 | 0.001 |
| Kidney disease | 10.5 | 10.3 | 11.2 | 11.7 | 6.5 | 9.7 | 11.1 | 0.001 |
| Liver disease | 0.4 | 0.4 | 0.4 | 0.5 | 0.3 | 0.4 | 0.5 | 0.001 |
| Malignancy | 5.6 | 5.4 | 5.8 | 6.0 | 4.2 | 5.3 | 7.4 | 0.001 |
| Obesity | 12.9 | 9.2 | 12.6 | 14.0 | 17.0 | 14.4 | 13.8 | 0.001 |
| COPD | 7.4 | 7.6 | 7.4 | 7.9 | 5.9 | 6.6 | 8.8 | 0.001 |
| CEVD | 0.7 | 0.7 | 0.8 | 0.9 | 0.5 | 0.6 | 0.8 | 0.001 |
| Total | First wave | Second wave | Third wave | Fourth wave | Fifth wave | Sixth wave | P-value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Admissions | ||||||||||||||
| ≤17 | 6,568 | 583 | (8.9%) | 16,22 | (24.7%) | 1,021 | (15.5%) | 657 | (10%) | 1,764 | (26.9%) | 921 | (14%) | 0.001 |
| 18–49 | 99,570 | 18,223 | (18.3%) | 23,525 | (23.6%) | 18,542 | (18.6%) | 13,669 | (13.7%) | 20,660 | (20.7%) | 4,951 | (5%) | 0.001 |
| 50–59 | 78,535 | 18,524 | (23.6%) | 19,534 | (24.9%) | 19,432 | (24.7%) | 11,560 | (14.7%) | 6,262 | (8%) | 3,223 | (4.1%) | 0.001 |
| 60–79 | 178,667 | 45,100 | (25.2%) | 44,052 | (24.7%) | 48,808 | (27.3%) | 18,198 | (10.2%) | 13,267 | (7.4%) | 9,242 | (5.2%) | 0.001 |
| ≥80 | 125,834 | 30,642 | (24.4%) | 35,998 | (28.6%) | 36,365 | (28.9%) | 5,806 | (4.6%) | 11,707 | (9.3%) | 5,316 | (4.2%) | 0.001 |
| ICU | ||||||||||||||
| ≤17 | 490 | 95 | (19.4%) | 109 | (22.2%) | 74 | (15.1%) | 62 | (12.7%) | 111 | (22.7%) | 39 | (8%) | 0.001 |
| 18–49 | 10,227 | 1,493 | (14.6%) | 2,186 | (21.4%) | 1,957 | (19.1%) | 1,513 | (14.8%) | 2,633 | (25.7%) | 445 | (4,4%) | 0.001 |
| 50–59 | 11,187 | 2,117 | (18.9%) | 2,733 | (24.4%) | 2,994 | (26.8%) | 1,705 | (15.2%) | 1,240 | (11.1%) | 398 | (3.6%) | 0.001 |
| 60–79 | 28,548 | 5,862 | (20.5%) | 7,159 | (25.1%) | 8,300 | (29.1%) | 3,537 | (12.4%) | 2,526 | (8.8%) | 1,164 | (4.1%) | 0.001 |
| ≥80 | 2,372 | 342 | (14.4%) | 754 | (31.8%) | 687 | (29%) | 185 | (7.8%) | 248 | (10.5%) | 156 | (6.6%) | 0.001 |
| Deaths | ||||||||||||||
| ≤l7 | 27 | 4 | (14.8%) | 7 | (25.9%) | 6 | (22.2%) | 2 | (7.4%) | 6 | (22.2%) | 2 | (7.4%) | 0.001 |
| 18–49 | 1,282 | 345 | (26.9%) | 300 | (23.4%) | 253 | (19.7%) | 92 | (7.2%) | 222 | (17.3%) | 70 | (5.5%) | 0.001 |
| 59–59 | 3,274 | 905 | (27.6%) | 760 | (23.2%) | 861 | (26.3%) | 277 | (8.5%) | 343 | (10.5%) | 128 | (3.9%) | 0.001 |
| 60–79 | 25,427 | 7,937 | (31.2%) | 5,914 | (23.3%) | 7,074 | (27.8%) | 1,871 | (7.4%) | 1,733 | (6.8%) | 898 | (3.5%) | 0.001 |
| ≥80 | 40,855 | 11,707 | (28.7%) | 11,111 | (27.2%) | 12,041 | (29.5%) | 1,499 | (3.7%) | 3,127 | (7.7%) | 1,370 | (3.4%) | 0.001 |
| Hospitalizations | Deaths | |||
|---|---|---|---|---|
| Events | (95% CI) | Events | (95% CI) | |
| RandomForest | ||||
| Observed | 136,658 | (NA) | 12,595 | (NA) |
| Estimated | 251,830 | (216,99–286,663) | 37,673 | (317,13–43,633) |
| Averted | 115,172 | (80,339–150,005) | 25,078 | (191,18–31,038) |
| ElasticNet | ||||
| Observed | 136,658 | (NA) | 12,595 | (NA) |
| Estimated | 307,617 | (214,502–400,733) | 37,141 | (15,143–59,138) |
| Averted | 170,959 | (77,844–264,075) | 24,546 | (2,548–46,543) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).